Posted on behalf of Prof. Terry Rabbitts: ---------------------------------------------
Post-doctoral post at ICR to develop LMO2 PROTAC compounds for leukaemia treatment Our Chromosomal Translocation and Intracellular Antibody Therapeutics Group is within the Division of Cancer Therapeutics and is focused on new strategies using intracellular antibodies, and derivates, for therapy aimed at hard-to-drug chromosomal translocation gene products. This work includes intracellular antibodies for inhibiting transcription factors and protein-protein interactions. The approach so far has resulted in compounds that bind to the chromosomal translocation LMO2 transcription factor and that effect T cell leukaemia cell growth. The aim is to develop these compounds into drugs for refractory T-cell acute leukaemias. All the scientific expertise is in place to make this possible and our approach is multi-disciplinary, integrating molecular biology, cell biology, antibody design, structural biology, and chemical biology. The post is part of a CR-UK funded Therapeutic Catalyst Award in collaboration with Professor Angela Russell (University of Oxford, Dept of Chemistry). We aim to develop our LMO2 binding compounds to pre-clinical efficacy using structure-based drug evolution. These will be the first compounds to be derived from an intracellular antibody binding site that have progressed towards phase I clinical trials. The post should lead to further work in the group to drug using our intracellular antibody approach. If you are interested in developing antibody derived compounds using recombinant protein expression and structural biology for cancer drug development, apply for the postdoctoral position (ID624) available in Professor Terry Rabbitts' group within the Division. You should have a PhD in a biological subject and have experience in working with recombinant proteins, in particular antibodies and transcription factors. You should have experience with protein engineering and as well as in methods such as X-ray crystallography. Experience with cell-based models will be needed for evaluation of compounds binding to LMO2. The post holder will be responsible for protein production and purification, protein crystallisation, structure determination by X-ray crystallography and subsequent cell-based analysis of compounds. We benefit from excellent access to Diamond Light Source synchrotron at the Harwell Science and Innovation campus, Didcot, UK, for X-ray data collection. The Institute of Cancer Research (ICR), London, is one of the world's most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. Today, the ICR leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment. Together with our hospital partner The Royal Marsden, we are rated in the top four centres for cancer research and treatment worldwide. As well as being a world-class institute, we are a college of the University of London. The ICR is committed to our mission to make the discoveries that defeat cancer. ICR is split between labs in Chelsea and Sutton and the Division of Cancer Therapeutics is located in the new Centre for Cancer Drug Discovery building at the Sutton site. It is dedicated to the discovery and development of novel therapeutics for the treatment of cancer. The starting salary will be in the range £40,107 to £42,402 p.a. inclusive (based on previous postdoctoral experience). The post is offered on a fixed term contract of up to 1.5 years. Informal enquiries to terry.rabbi...@icr.ac.uk<mailto:terry.rabbi...@icr.ac.uk> Please DO NOT send your application to Professor Rabbitts but apply via the e-recruitment system on our website www.icr.ac.uk<http://www.icr.ac.uk/>. For more details see the following link: https://jobs.icr.ac.uk/vacancies/661/postdoctoral-training-fellow-cr-uk-therapeutic-catalyst-grant-prof-t-rabbitts.html Closing date: 31st July 2023 Prof. Terry Rabbitts FRS FMedSci Institute of Cancer Research 15 Cotswold Road, Sutton, London, SM2 5NG, UK NOTICE AND DISCLAIMER This e-mail (including any attachments) is intended for the above-named person(s). If you are not the intended recipient, notify the sender immediately, delete this email from your system and do not disclose or use for any purpose. We may monitor all incoming and outgoing emails in line with current legislation. We have taken steps to ensure that this email and attachments are free from any virus, but it remains your responsibility to ensure that viruses do not adversely affect you. Cancer Research UK Registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247) A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered Office Address: 2 Redman Place, London, E20 1JQ ######################################################################## To unsubscribe from the CCP4BB list, click the following link: https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB&A=1 This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list hosted by www.jiscmail.ac.uk, terms & conditions are available at https://www.jiscmail.ac.uk/policyandsecurity/
